<p>Zydus Cadila on Thursday said it has received tentative approval from the US health regulator to market Linagliptin tablets, used to treat type 2 diabetes in adults.</p>.<p>Zydus Cadila has received tentative approval from the US Food and Drug Administration (USFDA) to market Linagliptin tablets in the strength of 5 mg, it said in a BSE filing.</p>.<p>Zydus Cadila is part of the Cadila Healthcare group.</p>.<p>The company said the newly approved medication will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.</p>.<p>The group now has 310 approvals and has so far filed over 390 abbreviated new drug applications since the commencement of the filing process in the financial year 2003-04.</p>.<p>Linagliptin tablets are used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.</p>.<p>Shares of Cadila Healthcare were trading 0.88 per cent lower at Rs 414.75 apiece on BSE. </p>
<p>Zydus Cadila on Thursday said it has received tentative approval from the US health regulator to market Linagliptin tablets, used to treat type 2 diabetes in adults.</p>.<p>Zydus Cadila has received tentative approval from the US Food and Drug Administration (USFDA) to market Linagliptin tablets in the strength of 5 mg, it said in a BSE filing.</p>.<p>Zydus Cadila is part of the Cadila Healthcare group.</p>.<p>The company said the newly approved medication will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.</p>.<p>The group now has 310 approvals and has so far filed over 390 abbreviated new drug applications since the commencement of the filing process in the financial year 2003-04.</p>.<p>Linagliptin tablets are used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.</p>.<p>Shares of Cadila Healthcare were trading 0.88 per cent lower at Rs 414.75 apiece on BSE. </p>